Abivax Raises $747.5M Through ADS Offering

Abivax, a biotechnology company focused on chronic inflammatory diseases, has successfully concluded its offering of American Depositary Shares (ADSs) in the U.S., resulting in gross proceeds of approximately $747.5 million (€637.5 million). Underwriters fully exercised their option to buy an additional 1,523,400 ADSs, enhancing the offering's total to 11,679,400 ADSs. Net proceeds, after deducting commissions and expenses, are estimated at $700.3 million (€597.2 million), earmarked for specific company allocations.

The offering price per ADS was set at $64, reflecting a 21% premium over recent trading prices. The ADSs are publicly listed on the Nasdaq Global Market under the ticker symbol "ABVX," while the company's ordinary shares trade on the Euronext Paris market.